Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1957 studies found for:    alzheimer
Show Display Options
Rank Status Study
41 Completed Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: AADvac1;   Other: Placebo
42 Active, not recruiting A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders
Condition: Alzheimer's Disease (AD) and Related Disorders
Intervention:
43 Completed Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
Condition: Alzheimer's Disease
Intervention:
44 Completed An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
Condition: Alzheimer Type Dementia
Interventions: Drug: Aricept;   Drug: INM-176
45 Completed
Has Results
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: AC-3933;   Other: Sugar Pill
46 Completed
Has Results
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine transdermal patch;   Drug: Placebo
47 Completed
Has Results
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Donepezil
48 Terminated Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes
Condition: Alzheimer's Disease
Intervention:
49 Completed Randomized Trial of a Nutritional Supplement in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Dietary Supplement: Resveratrol with Glucose, and Malate;   Dietary Supplement: Placebo
50 Unknown  Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Octohydroaminoacridine Succinate Tablets;   Drug: Octohydroaminoacridine succinate Tablets;   Drug: Placebo
51 Completed
Has Results
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: Placebo
52 Unknown  Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)
Condition: Alzheimer Disease
Interventions: Drug: alphatocopherol;   Drug: Selenium;   Drug: Placebo replacement for vitamin E;   Drug: Placebo replacement for Selenium
53 Completed Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research
Condition: Alzheimer's Disease
Intervention: Other: Actigraphy and video recording signal
54 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab
55 Completed
Has Results
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Interferon beta-1a;   Drug: Placebo
56 Active, not recruiting ATP in Alzheimer Disease
Condition: Alzheimer's Disease
Interventions: Drug: ADENOSINE TRIPHOSPHATE;   Drug: PLACEBO
57 Active, not recruiting 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: AADvac1
58 Completed Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: ACC-001 (vanutide cridificar)
59 Completed Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Condition: Alzheimer Disease
Intervention: Drug: xaliproden (SR57746A)
60 Completed
Has Results
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2);   Drug: Rivastigmine 9.5 mg/24 h (10 cm^2);   Drug: Rivastigmine 13.3 mg/24 h (15 cm^2);   Drug: Placebo

First Page    Show previous page of results Previous Page (21-40) Studies Shown (41-60) Next Page (61-80) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.